Systems biology analysis of protein‐drug interactions

Drugs induce global perturbations at the molecular machinery level because their cognate targets are involved in multiple biological functions or because of off‐target effects. The analysis or the prediction of such systems level consequences of drug treatment therefore requires the application of systems biology concepts and methods. In this review, we first summarize the methods of chemical proteomics that can measure unbiased and proteome‐wide drug protein target spectra, which is an obvious necessity to perform a global analysis. We then focus on the introduction of computational methods and tools to relate such target spectra to global models such as pathways and networks of protein‐protein interactions, and to integrate them with existing protein functional annotations. In particular, we discuss how drug treatment can be mapped onto likely affected biological functions, how this can help identifying drug mechanisms of action, and how such mappings can be exploited to predict potential side effects and to suggest new indications for existing compounds.

[1]  Ioannis Xenarios,et al.  DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions , 2002, Nucleic Acids Res..

[2]  James S. Duncan,et al.  An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics , 2008, Molecular & Cellular Proteomics.

[3]  G. Superti-Furga,et al.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.

[4]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[5]  G. Superti-Furga,et al.  The chemokine interleukin‐8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia , 2008, Molecular oncology.

[6]  E. Masuda,et al.  Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection , 2008, Transplantation.

[7]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[8]  E. Petricoin,et al.  Proteins, drug targets and the mechanisms they control: the simple truth about complex networks , 2007, Nature Reviews Drug Discovery.

[9]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[10]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[11]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[12]  Briana Foley,et al.  Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. , 2010, Chemistry & biology.

[13]  Y. Zhang,et al.  IntAct—open source resource for molecular interaction data , 2006, Nucleic Acids Res..

[14]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[15]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. , 2006, Human molecular genetics.

[16]  G. Superti-Furga,et al.  Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily , 2009, European journal of clinical investigation.

[17]  Pall I. Olason,et al.  A human phenome-interactome network of protein complexes implicated in genetic disorders , 2007, Nature Biotechnology.

[18]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[19]  Albert J R Heck,et al.  Revealing promiscuous drug-target interactions by chemical proteomics. , 2009, Drug discovery today.

[20]  G. Superti-Furga,et al.  An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B , 2011, Molecular Cancer Therapeutics.

[21]  P. Robinson,et al.  Walking the interactome for prioritization of candidate disease genes. , 2008, American journal of human genetics.

[22]  A. Heimberger,et al.  A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. , 2007, Cancer research.

[23]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[24]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[25]  Xiaodong Wang,et al.  Diazonamide toxins reveal an unexpected function for ornithine δ-amino transferase in mitotic cell division , 2007, Proceedings of the National Academy of Sciences.

[26]  G. Superti-Furga,et al.  Target profiling of small molecules by chemical proteomics. , 2009, Nature chemical biology.

[27]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[28]  Sang J. Chung,et al.  Identification of proteins binding to decursinol by chemical proteomics. , 2008, Journal of microbiology and biotechnology.

[29]  B. Nare,et al.  2,4-Diaminopyrimidines as Potent Inhibitors of Trypanosoma brucei and Identification of Molecular Targets by a Chemical Proteomics Approach , 2011, PLoS neglected tropical diseases.

[30]  Luana Licata,et al.  Searching the MINT Database for Protein Interaction Information , 2003, Current protocols in bioinformatics.

[31]  Patricia Rodriguez-Tomé,et al.  MMsINC: a large-scale chemoinformatics database , 2008, Nucleic Acids Res..

[32]  Gary D Bader,et al.  NetPath: a public resource of curated signal transduction pathways , 2010, Genome Biology.

[33]  P. Bork,et al.  Proteome survey reveals modularity of the yeast cell machinery , 2006, Nature.

[34]  Seth I. Berger,et al.  Systems Pharmacology of Arrhythmias , 2010, Science Signaling.

[35]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[36]  Damian Szklarczyk,et al.  STITCH 2: an interaction network database for small molecules and proteins , 2009, Nucleic Acids Res..

[37]  G. Drewes,et al.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. , 2011, ACS chemical biology.

[38]  Thomas Lengauer,et al.  Improved scoring of functional groups from gene expression data by decorrelating GO graph structure , 2006, Bioinform..

[39]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[40]  Bruce L. Booth,et al.  Opinion: Prospects for productivity , 2004, Nature Reviews Drug Discovery.

[41]  Weidong Zhang,et al.  The inhibitory activities of the components of Huang-Lian-Jie-Du-Tang (HLJDT) on eicosanoid generation via lipoxygenase pathway. , 2011, Journal of ethnopharmacology.

[42]  G. Superti-Furga,et al.  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells , 2009, Leukemia.

[43]  G. Superti-Furga,et al.  Charting the molecular network of the drug target Bcr-Abl , 2009, Proceedings of the National Academy of Sciences.

[44]  B. Cravatt,et al.  Chemical Strategies for Functional Proteomics* , 2002, Molecular & Cellular Proteomics.

[45]  Hyungwon Choi,et al.  Significance Analysis of Spectral Count Data in Label-free Shotgun Proteomics*S , 2008, Molecular & Cellular Proteomics.

[46]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[47]  M. Affolter,et al.  Proteomics at the center of nutrigenomics: comprehensive molecular understanding of dietary health effects. , 2009, Nutrition.

[48]  Aurélien Grosdidier,et al.  SwissDock, a protein-small molecule docking web service based on EADock DSS , 2011, Nucleic Acids Res..

[49]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[50]  Peng Jiang,et al.  Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..

[51]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[52]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[53]  Christoph Steinbeck,et al.  Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..

[54]  Andrew H. Thompson,et al.  Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. , 2003, Analytical chemistry.

[55]  Yoshiya Oda,et al.  Quantitative chemical proteomics for identifying candidate drug targets. , 2003, Analytical chemistry.

[56]  C. Anfinsen,et al.  Selective enzyme purification by affinity chromatography. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[58]  Akhilesh Pandey,et al.  Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. , 2009, Methods in molecular biology.

[59]  Brett R. Murphy,et al.  Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. , 2010, Chemistry & biology.

[60]  J. Cox,et al.  Proteomics strategy for quantitative protein interaction profiling in cell extracts , 2009, Nature Methods.

[61]  Karl Mechtler,et al.  General statistical modeling of data from protein relative expression isobaric tags. , 2011, Journal of proteome research.

[62]  Zhi-xiang Shen,et al.  Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia , 2008, Proceedings of the National Academy of Sciences.

[63]  G. Superti-Furga,et al.  A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells , 2010, Leukemia.

[64]  Florian P Breitwieser,et al.  Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. , 2009, Journal of proteome research.

[65]  Matthew R. Laird,et al.  Protein Protein Interaction Network Evaluation for Identifying Potential Drug Targets , 2009 .

[66]  Linfeng Wu,et al.  Role of spectral counting in quantitative proteomics , 2010, Expert review of proteomics.

[67]  Giulio Superti-Furga,et al.  A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib , 2010, PLoS Comput. Biol..

[68]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[69]  M. Mann,et al.  Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics , 2009, Molecular & Cellular Proteomics.

[70]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[71]  Bernhard Kuster,et al.  Profiling Core Proteomes of Human Cell Lines by One-dimensional PAGE and Liquid Chromatography-Tandem Mass Spectrometry*S , 2003, Molecular & Cellular Proteomics.

[72]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[73]  Alexander R. Pico,et al.  WikiPathways: Pathway Editing for the People , 2008, PLoS biology.

[74]  David S. Wishart,et al.  SMPDB: The Small Molecule Pathway Database , 2009, Nucleic Acids Res..

[75]  F. Boisvert,et al.  Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes , 2008, The Journal of cell biology.

[76]  T. Terada,et al.  Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. , 2004, Bioorganic & medicinal chemistry.

[77]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[78]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[79]  T. Barrette,et al.  Probabilistic model of the human protein-protein interaction network , 2005, Nature Biotechnology.

[80]  C. Coban,et al.  TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines , 2008, Nature.

[81]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[82]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[83]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[84]  Choong Yong Ung,et al.  Are herb-pairs of traditional Chinese medicine distinguishable from others? Pattern analysis and artificial intelligence classification study of traditionally defined herbal properties. , 2007, Journal of ethnopharmacology.

[85]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[86]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Kussmann Role of proteomics in nutrigenomics and nutrigenetics , 2009, Expert review of proteomics.

[88]  M. Vidal,et al.  Networking metabolites and diseases , 2008, Proceedings of the National Academy of Sciences.

[89]  N. Gray,et al.  In situ kinase profiling reveals functionally relevant properties of native kinases. , 2011, Chemistry & biology.

[90]  Bin Fang,et al.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer , 2010, Nature chemical biology.

[91]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[92]  R. Aebersold,et al.  Mass Spectrometry and Protein Analysis , 2006, Science.